Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutathera in adolescent GEP-NET and PPGL
NCT04711135Phase 2Active, not recruiting
- Sponsor
- Advanced Accelerator Applications
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), pheochromocytoma and Paraganglioma (PGL), sponsored by Advanced Accelerator Applications. Primary endpoints: Absorbed Radiation Doses in Target Organ at 8 days and Incidence of Adverse Events and Lab Toxicities After 1st Lutathera Administration at 56 days. Started Aug 2022; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT04711135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711135.